Skip directly to site content
Are You Still There?
Due to inactivity, you will be signed out in two minutes unless you click 'Continue'.

Are you still there?

Due to inactivity, you will be signed out in two minutes unless
you click 'Continue'.

Panel:   Isolates with New or Novel Antibiotic Resistance (NEW)
AR Bank # 1328 Pseudomonas aeruginosa
Study ID: NEW-39

Biosample Accession #: SAMN50502207

mCIM Result: Positive    

Collection Year: 2020
Location: USA
Source: Urine
MLST: ST1203(Pasteur)

MICs obtained by broth microdilution. Modal MIC is reported.

MIC results for each antimicrobial agent for an isolate may commonly be ± 1 log2 (doubling dilution) different than what is posted on the FDA & CDC AR Bank website because this is the normal technical variability of antimicrobial susceptibility testing (see J. H. Jorgensen. 1993. J Clin Microbiol. Vol 31[11]: 2841-2844).

Note: AR- 0349 Escherichia coli  has been removed from the collection and is now available at ATCC under catalog # BAA-3170

Panel:  Isolates with New or Novel Antibiotic Resistance (NEW)


MIC (μg/ml) Results and Interpretation
Drug MIC (μg/ml) INT
Amikacin >64R
Aztreonam >64R
Cefepime >32R
Cefepime/zidebactam 42---
Ceftazidime >128R
Ceftazidime/avibactam 1>16R
Ceftolozane/tazobactam 1>16R
Ciprofloxacin >8R
Colistin 21I
Imipenem 64R
Imipenem/relebactam 1>64R
Imipenem+chelators 31---
Levofloxacin >8R
Meropenem >8R
Piperacillin/tazobactam 1>128R
Tobramycin >16R
S – I –R Interpretation (INT) derived from CLSI 2025 M100 S35
1 Reflects MIC of first component
2 Clinical and PK/PD data demonstrate colistin has limited clinical efficacy, even if an intermediate result is obtained. Alternative agents are strongly preferred. Colistin should be used in combination with one or more active antimicrobial agents. Consultation with an infectious disease specialist is recommended.
3 Screen for metallo-beta-lactamase production [Rasheed et al. Emerging Infectious Diseases. 2013. 19(6):870-878]
4 Cefepime to zidebactam ratio (1:1)
Device manufacturers and users of FDA cleared devices shall consult the FDA’s Antibacterial Susceptibility Test Interpretive Criteria       website for breakpoints recognized or recommended by FDA, and for information regarding FDA exceptions or additions to the applicable, recognized consensus standard.
Molecular Mechanisms of Resistance
CategoryGene
Aminoglycoside aph(3')-IIb, aph(6)-Id, rmtB4
Beta-lactam DIM-1, NDM-1, OXA-395, PDC-19A, PME-1
Bleomycin ble-MBL
Efflux pumps/Other mexA, mexE, qacEdelta1
Fosfomycin fosA
Macrolide-Lincosamide-Streptogramin ere(A), mph(A), mph(E), msr(E)
Phenicols/Bicyclomycins bcr1, floR, floR2
Quinolone QnrVC1
Sulfonamides sul1
Tetracyclines tet(G), tmexD2, toprJ1
Trimethoprim dfrA5
 
Disclaimer:

Antimicrobial Resistance (AR) gene prediction was performed using a combined and deduplicated AR database (ResGANNCBI) from ResFinder, ARG-ANNOT, and NCBI AMRFinder(primary Database) accessed on 2022-09-15. AR drug classes are assigned according to these databases. This analysis does not include mutations that may result in antimicrobial resistance, or resistance determinants added to newer versions of databases used, or other antimicrobial resistance gene databases. Additional AR genes other than those listed, may be present. For resistance determinant detection, 99-100% sequence identity and 100% sequence coverage from GAMMA (primary AR gene calling tool) and SRST2 was used. GAMMA uses amino acid sequence to assign gene alleles from assemblies; SRST2 uses nucleotide sequence to assign gene alleles from sequencing reads and is used to resolve AR gene calls located on the edges of assembly scaffolds detected by GAMMA. Biosample accession numbers have been provided so that users can analyze the raw sequencing data on their own, if so desired.

*MLST Type (and scheme), as determined by Torsten Seemann's MLST program. For Enterobacterales the Pasteur MLST schemes are used except for E. coli for which both the Pasteur and Achtman schemes are reported.

Truncated porins are defined as porin genes detected with =80% sequence identity and =80% sequence coverage and predicted to have an internal stop codon by c-SSTAR (https://github.com/chrisgulvik/c-SSTAR).

** Prescence of Efflux Pump may not be associated with resistance.

Propagation
MEDIUM
Medium: Trypticase Soy Agar with 5% Sheep Blood (BAP)

GROWTH CONDITIONS
Temperature: 35°C
Atmosphere: Aerobic

PROPAGATION PROCEDURE

Remove the sample vial to a container with dry ice or a freezer block. Keep vial on ice or block. (Do not let vial content thaw)

Open vial aseptically to avoid contamination

Using a sterile loop, remove a small amount of frozen isolate from the top of the vial

Aseptically transfer the loop to BAP

Use streak plate method to isolate single colonies

Incubate inverted plate at 35°C ± 2°C for 18-24 hrs.
Storage Temperature & Biosafety
STORAGE TEMPERATURE: -70°C

BIOSAFETY LEVEL: 2

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the current publication of 'BioSafety in Microbiological and Biomedical Laboratories' from the U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, and National Institutes of Health.

Please Note: This AR Bank panel includes isolates that are pan-resistant, meaning they are susceptible to none of the antimicrobial agents tested which may include those commonly used to treat infections with these organisms. This represents an additional risk to staff working with these organisms and should be considered as part of the receiving facility risk assessment required by the Biosafety Compliance Agreement. The increased difficulty in treatment of any infection with those isolates should also be a consideration in deciding which protocols to use and precautions to take for working with these isolates.



Disclaimer:

This product is sent with the condition that you are responsible for its safe storage, handling, and use. All materials are the property of the Centers for Disease Control and Prevention (CDC) and have been made available on behalf of the Food and Drug Administration (FDA). This material is not for use in human subjects and may not be redistributed. While CDC uses reasonable efforts to include accurate and up-to-date information on this product sheet, CDC makes no warranties or representations as to its accuracy. CDC is not liable for damages arising from the misidentification or misrepresentation of cultures. Please refer to the Standard Letter Agreement (SLA) for further details regarding the use of this product.
Isolate History
Date Action Performed
08/19/25Sequence Accession # changed: from '---' to 'SAMN50502207'
06/26/25New Isolate added to panel
Top of Page
TOP